 "Lupin gets USFDA nod for generic potassium deficiency drug")
US-based Gavis has received final approval from US Food and Drug Administration (USFDA) to market a generic equivalent of Actavis Labs FL Inc's potassium chloride extended release capsules in various strengths, Lupin Ltd said in a regulatory filing.
Lupin had announced acquisition of Somerset-based Gavis Pharmaceuticals on July 23 last year.
Also Read
According to IMS MAT June sales data, potassium chloride extended-release capsules had US sales of $75.4 million.
Lupin stock closed at Rs 1,595.30, up 0.36%, on BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%